BridgeMD
Tests treatment safety and results for Trigeminal Herpetic Neuralgia
Official title Efficacy of Electroacupuncture Combined With Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol
ClinicalTrials.gov ID: NCT06261801
What this study is testing
- What it's testing
- Trigeminal herpetic neuralgia is a common type of Zoster-associated Pain (ZAP), which troubles individuals in all ages and burdens society all over the world. Eleactroaupuncture (EA) is increasingly used in the treatment of ZAP due to its advantages such as low price, high safety, no adverse reactions, and high patient acceptance.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- meet the aforementioned diagnostic criteria for trigeminal ZAP, with a disease duration of 1 to 3 months;
- have a visual analog scale (VAS) score of 4 points ≤ VAS ≤ 7 points;
- be between 18 and 85 years old, regardless of gender;
- have clear consciousness, the ability to distinguish pain, and complete basic communication;
- voluntarily participate in the study, sign a written informed consent form, and fully understand the plan.
You likely can't join if
- do not meet the above-mentioned inclusion criteria;
- have concomitant herpes zoster on the trunk or extremities, or other special types of herpes zoster like meningeal herpes zoster or visceral herpes...
- are pregnant or lactating patients;
- are allergic to pregabalin or acupuncture stimulation;
- have severe organ damage, cognitive dysfunction, mental disorder, aphasia, or other serious diseases that hinder cooperation with treatment;
- have severe skin diseases;
See the full eligibility criteria
- meet the aforementioned diagnostic criteria for trigeminal ZAP, with a disease duration of 1 to 3 months;
- have a visual analog scale (VAS) score of 4 points ≤ VAS ≤ 7 points;
- be between 18 and 85 years old, regardless of gender;
- have clear consciousness, the ability to distinguish pain, and complete basic communication;
- voluntarily participate in the study, sign a written informed consent form, and fully understand the plan.
- do not meet the above-mentioned inclusion criteria;
- have concomitant herpes zoster on the trunk or extremities, or other special types of herpes zoster like meningeal herpes zoster or visceral herpes zoster;
- are pregnant or lactating patients;
- are allergic to pregabalin or acupuncture stimulation;
- have severe organ damage, cognitive dysfunction, mental disorder, aphasia, or other serious diseases that hinder cooperation with treatment;
- have severe skin diseases;
- have a pacemaker;
- have been or are currently participating in other clinical studies within the past 3 months.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.